HilleVax plummets after norovirus vaccine fails in mid-stage study

HilleVax

08/07/2024 13:31

** Shares of vaccine developer HilleVax  HLVX.O  fall ~90.1%
to $1.40 premarket
    ** Co says its norovirus vaccine HIL-214 did not meet its
goals when tested in infants of about 5 months of age
    ** Says it will discontinue further development of the
vaccine in infants
    ** In the mid-stage study, the vaccine did not show efficacy
against gastroenteritis, which is inflammation of the stomach
lining
    ** Norovirus causes vomiting, diarrhea and other foodborne
illnesses
    ** Up to last close, stock down 12.4% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))